Following a two-year probe, Canadian authorities have decided there was insufficient evidence that three large drug makers tried to thwart generic rivals by blocking access to samples of their medicine, an issue that has caused controversy in  the U.S., as well.

Generic drug makers are required to run tests proving their low-cost alternatives act similarly as the brand-name medicines, but samples are needed to prove their case. Acting on a tip, Canada’s Competition Bureau began probing Pfizer (PFE), Celgene (CELGZ) (CELG), and Sanofi (SNY) for allegedly refusing to provide samples to generic manufacturers and preventing distributors from providing the drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy